The content is available as a PDF (828.5 KB).
†
Potential conflict of interest: Nothing to report.
References
- 1. Porter D. ASH 2009 meeting report: The top 10 clinically‐oriented abstracts in hematopoietic stem cell transplantation. Am J Hematol 2009; 85: 193–196. [Google Scholar]
- 2. Mathias C,Mick R,Grupp S, et al. Soluble interleukin‐2 receptor concentration as a biochemical indicator for acute graft‐versus‐host disease after allogeneic bone marrow transplantation. J Hematotherapy Stem Cell Res 2000; 9: 393–400. [DOI] [PubMed] [Google Scholar]
- 3. Paczesny S,Levine J,Braun T,Ferrara J. Plasma biomarkers in graft‐versus‐host disease: A new era? Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2009; 15: 33–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. June C,Blazar B. Clinical application of expanded CD4+25+ cells. Seminars Immunol 2006; 18: 78–88. [DOI] [PubMed] [Google Scholar]
- 5. Flowers ME,Parker PM,Johnston LJ, et al. Comparison of chronic graft‐versus‐host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long‐term follow‐up of a randomized trial. Blood 2002; 100: 415–419. [DOI] [PubMed] [Google Scholar]
- 6. Shlomchik WD. Graft‐versus‐host disease. Nat Rev Immunol 2007; 7: 340–352. [DOI] [PubMed] [Google Scholar]
- 7. Socie G,Stone JV,Wingard JR, et al. Long‐term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl J Med 1999; 341: 14–21. [DOI] [PubMed] [Google Scholar]
- 8. Ma Q,Palmer L,Balogun J, et al. CCR5+T cells mediate alloimmune responses in human graft versus host disease. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2010; 16: S300–S301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ma Q,Gooley TA,Storb R. CCR5 Expression on cells from HLA‐matched unrelated marrow donors and graft‐versus‐host disease. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2010; 16: 132–133. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Cooke KR,Yanik G. Acute lung injury after allogeneic stem cell transplantation: Is the lung a target of acute graft‐versus‐host disease? Bone Marrow Transplant 2004; 34: 753–765. [DOI] [PubMed] [Google Scholar]
- 11. Yanik G,Cooke KR,Yanik G,Cooke KR. The lung as a target organ of graft‐versus‐host disease. Seminars Hematol 2006; 43: 42–52. [DOI] [PubMed] [Google Scholar]
- 12. Deeg HJ,Blazar BR,Bolwell BJ, et al. Treatment of steroid‐refractory acute graft‐versus‐host disease with anti‐CD147 monoclonal antibody ABX‐CBL. Blood 2001; 98: 2052–2058. [DOI] [PubMed] [Google Scholar]
- 13. Khoury H,Kashyap A,Adkins DR, et al. Treatment of steroid‐resistant acute graft‐versus‐host disease with anti‐thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059–1064. [DOI] [PubMed] [Google Scholar]
- 14. Appelbaum FR, editor. Thomas' Hematopoietic Cell Transplantation, Secondary Malignancies after Hematopoitic Cell Transplantation: 1638. Wiley‐Blackwell: Chichester, UK; 2009. [Google Scholar]
- 15. Karp JE,Sarkodee‐Adoo CB. Therapy‐related acute leukemia. Clin Lab Med 2000; 20: 71–81. [PubMed] [Google Scholar]
- 16. Curtis RE,Rowlings PA,Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904. [DOI] [PubMed] [Google Scholar]
- 17. Rizzo JD,Curtis RE,Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Tallman MS,Rowlings PA,Milone G, et al. Effect of postremission chemotherapy before human leukocyte antigen‐identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000; 96: 1254–1258. [PubMed] [Google Scholar]
- 19. Cahn JY,Labopin M,Sierra J, et al. No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute leukaemia working party of the European group for blood and marrow transplantation (EBMT). Brit J Haematol 2000; 110: 308–314. [DOI] [PubMed] [Google Scholar]
- 20. Beatty G,Smith J,Reshef R, et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen‐specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009; 15: 4944–4953. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Rooney C,Smith C,Ng C, et al. Infusion of cytoxic T cells for the prevention and treatment of Epstein‐Barr virus‐induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555. [PubMed] [Google Scholar]
- 22. Boue F,Gabarre J,Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV‐associated non‐Hodgkin's lymphoma. J Clin Oncol 2006; 24: 4123–4128. [DOI] [PubMed] [Google Scholar]
- 23. Ambinder RF. The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infection. Bone Marrow Transplant 2009; 44: 1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Lokhorst HM,Schattenberg A,Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem‐cell transplantation: Predictive factors for response and long‐term outcome. J Clin Oncol 2000; 18: 3031–3037. [DOI] [PubMed] [Google Scholar]
- 25. Salama M,Nevill T,Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179–1184. [DOI] [PubMed] [Google Scholar]
- 26. Alousi AM,Weisdorf DJ,Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft‐versus‐host disease: A randomized phase 2 trial from the blood and marrow transplant clinical trials network. Blood 2009; 114: 511–517. [DOI] [PMC free article] [PubMed] [Google Scholar]